Skip to main content
. 2020 Aug 4;95(5):e469–e479. doi: 10.1212/WNL.0000000000010019

Table 3.

Proportion of patients completing 52 weeks of erenumab treatment who achieved ≥50% reduction in monthly migraine days (MMDs) during the last 3 months of the active treatment phase (ATP) categorized by treatment response during the last 3 months of the double-blind treatment phase (DBTP)

graphic file with name NEUROLOGY2019018481TT3.jpg